Read more
18:01 · 13 January 2025

Moderna slumps 20% on harsh 2025 guidance revision 📉

-
-
Open account Download free app
Moderna (MRNA.US) started the week with an exceptionally dismal session, with a stock declining around 20%. Investors are selling off shares of the mRNA vaccine producer following...

Log in or create a free account to keep reading

Analyses by award-winning experts

Create account  Log in

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.

Join over 2 Million investors from around the world